MCID: HPT046
MIFTS: 55

Hepatic Veno-Occlusive Disease

Categories: Cardiovascular diseases, Gastrointestinal diseases, Liver diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hepatic Veno-Occlusive Disease

MalaCards integrated aliases for Hepatic Veno-Occlusive Disease:

Name: Hepatic Veno-Occlusive Disease 11 19 58 75 53 43 14 71 31 33
Sinusoidal Obstruction Syndrome 19 58
Veno-Occlusive Disease 11 53
Veno-Occlusive Disease of the Liver 33
Hepatic Venoocclusive Disease 75
Hepatic Vein Thrombosis 71
Hepatic Vein Occlusion 71
Venoocclusive Disease 71
Budd-Chiari Syndrome 71

Characteristics:


Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

Disease Ontology 11 DOID:0080177
MeSH 43 D006504
ICD10 31 K76.5
MESH via Orphanet 44 D006504
ICD10 via Orphanet 32 K76.5
UMLS via Orphanet 72 C0019156
Orphanet 58 ORPHA890
ICD11 33 762044088
UMLS 71 C0019154 C0019156 C0856761 more

Summaries for Hepatic Veno-Occlusive Disease

GARD: 19 A disorder characterized by damage of the hepatic sinusoidal endothelial cells of the hepatic venules that leads to venular occlusion and hepatocellular necrosis. It is usually the side effect of high dose chemotherapy in preparation for stem cell transplantation. Less frequently it may be caused by ingestion of plant alkaloids. The clinical signs and symptoms include hyperbilirubinemia, hepatomegaly, and fluid retention.

MalaCards based summary: Hepatic Veno-Occlusive Disease, also known as sinusoidal obstruction syndrome, is related to pulmonary edema and budd-chiari syndrome. An important gene associated with Hepatic Veno-Occlusive Disease is SERPINC1 (Serpin Family C Member 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Signaling by Receptor Tyrosine Kinases. The drugs Inotuzumab ozogamicin and Anti-Bacterial Agents have been mentioned in the context of this disorder. Affiliated tissues include liver, bone marrow and endothelial, and related phenotypes are hepatomegaly and renal insufficiency

Orphanet: 58 A rare vascular liver disease characterized by toxic injury to the hepatic sinusoidal capillaries that leads to obstruction of the small hepatic veins and sinusoids. Clinical manifestations include painful hepatomegaly, jaundice, and fluid retention that manifests by weight gain, edemas, and ascites.

Disease Ontology: 11 A hepatic vascular disease that is characterized by obstruction of some of the small veins of the liver.

Wikipedia: 75 Hepatic veno-occlusive disease (VOD) or veno-occlusive disease with immunodeficiency is a potentially... more...

Related Diseases for Hepatic Veno-Occlusive Disease

Diseases related to Hepatic Veno-Occlusive Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 529)
# Related Disease Score Top Affiliating Genes
1 pulmonary edema 31.3 SERPINC1 CXCL8 CSF3
2 budd-chiari syndrome 31.1 SERPINC1 PLG F3
3 pulmonary hypertension 31.1 VEGFA THBD SULT1A3 SERPINE1 FGF2 F3
4 hepatic coma 30.8 SERPINC1 F3
5 factor viii deficiency 30.7 SERPINC1 F8 F3
6 esophageal varix 30.7 THPO SERPINC1 F3
7 vitamin k deficiency bleeding 30.5 SERPINC1 F8 F3
8 mucositis 30.5 VEGFA CSF3 ABCB1
9 protein c deficiency 30.4 THBD SERPINE1 SERPINC1
10 antithrombin iii deficiency 30.4 SERPINC1 PLG F3
11 thrombophilia due to thrombin defect 30.4 THBD SERPINE1 SERPINC1 PLAT F8 F3
12 liver cirrhosis 30.4 THPO SLC17A5 SERPINC1 HFE F3
13 viral hepatitis 30.3 THPO THBD SLC17A5 HFE
14 varicose veins 30.3 VEGFA THBD SERPINC1 PLAT HFE CXCL8
15 toxic shock syndrome 30.3 SERPINC1 F3 CXCL8 CSF3
16 endocarditis 30.3 SERPINE1 SERPINC1 PLAT CXCL8
17 hemolytic uremic syndrome, atypical 1 30.3 THBD PLG F3
18 disseminated intravascular coagulation 30.3 THBD SERPINE1 SERPINC1 PLG PLAT F3
19 thrombotic thrombocytopenic purpura 30.3 THBD SERPINE1 SERPINC1 F8 F3
20 polycythemia 30.3 VEGFA THPO F3
21 hemophagocytic lymphohistiocytosis 30.3 F3 CXCL8 CSF3
22 nonbacterial thrombotic endocarditis 30.3 SERPINC1 PLG PLAT F3
23 bilirubin metabolic disorder 30.3 VEGFA SLC17A5 SERPINC1 F3 CXCL8 CSF3
24 mitral valve stenosis 30.2 SERPINC1 PLG PLAT F3
25 pericarditis 30.2 SLC17A5 CXCL8 AZU1
26 portal vein thrombosis 30.2 THPO THBD SERPINC1 PLG F8 F3
27 cardiac tamponade 30.2 PLG PLAT F8 F3
28 atrial heart septal defect 30.2 SERPINC1 PLG PLAT F3
29 purpura 30.2 THPO THBD SERPINC1 F3 CXCL8
30 exanthem 30.2 VEGFA F3 CXCL8 CSF3
31 arteriovenous malformation 30.2 VEGFA PLG PLAT F3
32 myeloproliferative neoplasm 30.2 THPO THBD FGF2 CSF3
33 patent ductus arteriosus 1 30.1 VEGFA F3 CXCL8
34 compartment syndrome 30.1 SERPINC1 PLG F8 F3
35 kidney disease 30.1 VEGFA THBD SERPINE1 HFE FGF2 CXCL8
36 behcet syndrome 30.1 VEGFA THBD SERPINC1 F3 CXCL8 CSF3
37 hemolytic-uremic syndrome 30.1 THBD SERPINE1 SERPINC1 PLG F3 CXCL8
38 sickle cell anemia 30.1 SERPINC1 F3 CSF3
39 hypersplenism 30.1 THPO SERPINC1 F3 CSF3
40 leukemia, acute lymphoblastic 30.0 TPMT THPO SERPINC1 CSF3 CD33 ABCB1
41 thrombosis 30.0 THBD SERPINE1 SERPINC1 PLG PLAT F8
42 vascular disease 30.0 VEGFA THBD SERPINE1 SERPINC1 PLAT FGF2
43 pancytopenia 30.0 TPMT THPO CSF3 CD33
44 poems syndrome 30.0 VEGFA FGF2 CXCL8 CSF3
45 thrombophlebitis 29.9 SERPINE1 SERPINC1 PLG PLAT F8 F3
46 acute leukemia 29.9 TPMT THPO CSF3 ABCB1
47 neutropenia 29.9 TPMT THPO CXCL8 CSF3 ABCB1
48 leukemia, chronic myeloid 29.9 VEGFA THPO CSF3 CD33 ABCB1
49 aspergillosis 29.9 PLG CXCL8 CSF3
50 leukemia, acute myeloid 29.9 VEGFA THPO FGF2 CXCL8 CSF3 CD33

Comorbidity relations with Hepatic Veno-Occlusive Disease via Phenotypic Disease Network (PDN):


Heart Disease

Graphical network of the top 20 diseases related to Hepatic Veno-Occlusive Disease:



Diseases related to Hepatic Veno-Occlusive Disease

Symptoms & Phenotypes for Hepatic Veno-Occlusive Disease

Human phenotypes related to Hepatic Veno-Occlusive Disease:

58 30 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hepatomegaly 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002240
2 renal insufficiency 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000083
3 ascites 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001541
4 elevated hepatic transaminase 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002910
5 jaundice 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000952
6 abdominal pain 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002027
7 respiratory failure 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002878
8 increased total bilirubin 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003573
9 increased body weight 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0004324
10 prolonged partial thromboplastin time 58 30 Frequent (33%) Frequent (79-30%)
HP:0003645
11 hepatic encephalopathy 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002480
12 abnormality of coagulation 58 Frequent (79-30%)

GenomeRNAi Phenotypes related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 ABCB1 AZU1 CD33 CSF3 CXCL8 F3
2 no effect GR00402-S-2 10.17 CSF3 F3 F8 FGF2 HFE PLAT

MGI Mouse Phenotypes related to Hepatic Veno-Occlusive Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.06 ABCB1 CD33 F3 F8 FGF2 HFE
2 liver/biliary system MP:0005370 9.86 ABCB1 HFE PLG SERPINC1 SERPINE1 SULT1A3
3 immune system MP:0005387 9.8 ABCB1 CD33 CSF3 F3 F8 HFE
4 hematopoietic system MP:0005397 9.5 ABCB1 CD33 CSF3 F3 F8 FGF2

Drugs & Therapeutics for Hepatic Veno-Occlusive Disease

Drugs for Hepatic Veno-Occlusive Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Inotuzumab ozogamicin Approved, Investigational Phase 4 635715-01-4
2 Anti-Bacterial Agents Phase 4
3 Antineoplastic Agents, Immunological Phase 4
4 Immunoglobulins Phase 4
5 Antibodies Phase 4
6 Antibiotics, Antitubercular Phase 4
7
Defibrotide Approved, Investigational Phase 3 83712-60-1
8
Heparin, bovine Approved, Investigational, Withdrawn Phase 3 9005-49-6 22833565 9812414 772
9
Reviparin Approved, Investigational Phase 3 9041-08-1
10
Alprostadil Approved, Investigational Phase 2, Phase 3 745-65-3 5280723
11 Anticoagulants Phase 3
12 Fibrinolytic Agents Phase 3
13 Platelet Aggregation Inhibitors Phase 3
14 Anti-Inflammatory Agents Phase 3
15 Coagulants Phase 3
16 Heparin, Low-Molecular-Weight Phase 3
17 Calcium heparin Phase 3
18 Cola Phase 3
19
bilirubin Phase 2, Phase 3 635-65-4 5280352
20 Orange Approved Phase 1, Phase 2
21
Acetylcysteine Approved, Investigational Phase 2 616-91-1 581 12035
22
Imatinib Mesylate Phase 1, Phase 2 220127-57-1
23 Protein Kinase Inhibitors Phase 1, Phase 2
24 HIV Protease Inhibitors Phase 2
25 Serine Proteinase Inhibitors Phase 2
26 Antithrombins Phase 2
27 Antithrombin III Phase 2
28
protease inhibitors Phase 2
29 Antiviral Agents Phase 2
30 Anti-Infective Agents Phase 2
31 Expectorants Phase 2
32 Antidotes Phase 2
33 Pharmaceutical Solutions Phase 2
34 N-monoacetylcystine Phase 2
35 Respiratory System Agents Phase 2
36 Antioxidants Phase 2
37 Protective Agents Phase 2
38
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
39
Oxaliplatin Approved, Investigational 61825-94-3 43805 11947679 6857599
40
Bevacizumab Approved, Investigational 216974-75-3 135329020
41
Protein C Approved
42
Atezolizumab Approved, Investigational 1380723-44-3
43
L-Glutamine Approved, Investigational, Nutraceutical 56-85-9 5961
44 Antimitotic Agents
45 Angiogenesis Inhibitors
46 Factor VIII
47 Protein S
48 Antibodies, Monoclonal
49 Immunologic Factors

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Using Ultrasound Elastography to Predict Development of Sinusoidal Obstruction Syndrome Active, not recruiting NCT03858530 Phase 4
2 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE Active, not recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
3 Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients Withdrawn NCT03963999 Phase 4 Contrast Enhanced Ultrasound (CEUS)
4 Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study Completed NCT00628498 Phase 3 Defibrotide
5 Prospective Randomized Study of the Incidence and Outcome of Veno-Occlusive Disease (VOD) With the Prophylactic Use of Defibrotide (DF) in Pediatric Stem Cell Transplantation Completed NCT00272948 Phase 2, Phase 3 Defibrotide
6 Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy Completed NCT00358501 Phase 3 Defibrotide
7 A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant Completed NCT02851407 Phase 3 Defibrotide
8 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
9 Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer Completed NCT00003674 Phase 3 dalteparin;standard therapy
10 Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT Active, not recruiting NCT02338440 Phase 2, Phase 3 lipoprostaglandin E1
11 Defibrotide for Hematopoietic Stem Cell Transplant Patients With Severe Hepatic Venocclusive Disease: A Phase I/II Study to Determine the Minimal Effective Dose Completed NCT00003966 Phase 2 defibrotide
12 Adjunct Targeted Biologic Inhibition in Children With Multivessel Intraluminal Pulmonary Vein Stenosis Completed NCT00891527 Phase 1, Phase 2 Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)
13 Phase II Open Label Study to Assess Efficacy of 5-day Defibrotide Treatment for Hepatic SOS/VOD Recruiting NCT04313036 Phase 2 Defibrotide
14 Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation Active, not recruiting NCT01886248 Phase 2 Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU
15 Prospective, Randomized Study Using N-Acetylcysteine as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation Not yet recruiting NCT04712435 Phase 2 N-acetylcysteine;Placebo
16 Hepatic Artery Infusion of CD34+ Cells, Isolated by the Isolex 300i Device, in Stem Cell Transplant Recipients With Hepatic Failure Due to Veno-occlusive Disease Withdrawn NCT00062543 Phase 1
17 Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic Veno-occlusive Disease in Children With Nephroblastoma or Acute Lymphoblastic Leukemia Unknown status NCT04168788
18 A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis. Unknown status NCT00563498 Glutamine
19 A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio® Completed NCT03032016
20 A Retrospective Study About Detection of Sinusoidal Obstruction Syndrome With Ultrasound After Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT04141735
21 Using Ultrasound Elastography to Predict Development of Sinusoidal Obstruction Syndrome Completed NCT02483481
22 Usefulness of Liver Stiffness Measurement in Predicting Hepatic Veno-Occlusive Disease Development in Patients Who Undergo HSCT: a Multicentric Prospective Study Completed NCT03426358
23 Prevention of the Hepatic Sinusoidal Obstruction Syndrome Secondary to Oxaliplatin-based Neoadjuvant Chemotherapy for Colorectal Liver Metastases by Means of Anticoagulants Completed NCT00885950
24 Pharmacogenetics of Veno-Occlusive Disease (VOD) in Children With Haematological Stem Cell Transplantation (HSCT) Completed NCT03664427
25 To Compare "Balloon Occluded Thrombolysis" With "Conventional Catheter Directed Thrombolysis" in Thrombotically Occluded DIPSS Stent in Patients of Budd- Chiari Syndrome. Completed NCT05117684
26 Balloon Angioplasty Alone Versus in Combination With Stent Placement for the Treatment of Budd-Chiari Syndrome in China: An Randomized Controlled Trial Completed NCT02201485
27 Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome Recruiting NCT03865589
28 A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS). Recruiting NCT05090345
29 Prospective Evaluation of Coagulation Status and Thromboelastometry Guided Management of Genetic and Acquired Thrombophilia in Patients With Portal Vein Thrombosis and Budd-Chiari Syndrome Recruiting NCT05123326
30 Vienna Vascular Liver Disease Study: Characterization of Patients With Vascular Liver Disease - a Registry With Biobank Recruiting NCT03541057
31 A Multicenter, Randomized, Open-label Study Evaluating the Efficacy and Safety of Hepatic Resection for Hepatocellular Carcinoma With Venous Tumor Thrombosis After Initial Atezolizumab Plus Bevacizumab Treatment Recruiting NCT04649489 Atezolizumab
32 Biomarkers of Endothelial Dysfunction in Pediatric Patients Receiving High Intensity Chemotherapy/Irradiation Active, not recruiting NCT03132337
33 Compassionate Use of Defibrotide for Patients With Veno-Occlusive Disease No longer available NCT00143546 Defibrotide
34 Defibrotide Compassionate Use Protocol for Patients With Life Threatening Veno-Occlusive Disease of the Liver No longer available NCT00263978 Defibrotide
35 Portal Vein Thrombosis in Cirrhosis: A Cohort Sudy Withdrawn NCT02275585

Search NIH Clinical Center for Hepatic Veno-Occlusive Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Antithrombin III, Human
ANTITHROMBIN III,RECOMBINANT

Cochrane evidence based reviews: hepatic veno-occlusive disease

Genetic Tests for Hepatic Veno-Occlusive Disease

Anatomical Context for Hepatic Veno-Occlusive Disease

Organs/tissues related to Hepatic Veno-Occlusive Disease:

MalaCards : Liver, Bone Marrow, Endothelial, Bone, Myeloid, Lung, Kidney

Publications for Hepatic Veno-Occlusive Disease

Articles related to Hepatic Veno-Occlusive Disease:

(show top 50) (show all 2941)
# Title Authors PMID Year
1
The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. 53 62
17015055 2006
2
Costs of allogeneic hematopoietic stem cell transplantation. 53 62
16858272 2006
3
Control of hepatic veno-occlusive disease with an antithrombin-III concentrate-based therapy. 53 62
16490079 2006
4
Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity. 53 62
15113990 2004
5
Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF). 53 62
12745658 2003
6
Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. 53 62
12199790 2002
7
Multiple organ dysfunction syndrome in hematopoietic stem cell transplantation. 53 62
12004245 2002
8
Portal vein thrombosis after hematopoietic cell transplantation: frequency, treatment and outcome. 53 62
11896430 2002
9
Growth factors and hemostasis: differential effects of GM-CSF and G-CSF on coagulation activation--laboratory and clinical evidence. 53 62
11669301 2001
10
Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer. 53 62
10650858 1999
11
Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. 53 62
10627640 1999
12
The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation. 53 62
10194118 1999
13
Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. 53 62
9827816 1998
14
Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. 53 62
9540759 1998
15
Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. 53 62
9058743 1997
16
Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation. 53 62
9052916 1997
17
Protein C, protein S and antithrombin III levels in the course of bone marrow and subsequent liver transplantation due to veno-occlusive disease. 53 62
9438165 1996
18
Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. 53 62
8807121 1996
19
Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. The BMT Team. 53 62
8602625 1996
20
Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate. 53 62
8704704 1996
21
Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis. 53 62
7858540 1994
22
Alteplase for hepatic veno-occlusive disease after bone marrow transplantation. 53 62
1354293 1992
23
Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation. 53 62
1351153 1992
24
Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation. 53 62
1349081 1992
25
Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia. 62
36031729 2023
26
Ultrasonographic monitoring of sinusoidal obstruction syndrome in patients treated with inotuzumab ozogamicin. 62
36308679 2022
27
Retrorsine Cooperates with Gut Microbiota to Promote Hepatic Sinusoidal Obstruction Syndrome by Disrupting the Gut Barrier. 62
36381109 2022
28
Effects of bicyclol on hepatic sinusoidal obstruction syndrome induced by Gynura segetum. 62
36447383 2022
29
Enoxaparin attenuates pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression. 62
36354295 2022
30
Model establishment and microarray analysis of mice with oxaliplatin‑induced hepatic sinusoidal obstruction syndrome. 62
36177905 2022
31
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors. 62
36473326 2022
32
Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome. 62
36042137 2022
33
Hepatic venous pressure gradient in sinusoidal obstruction syndrome: diagnostic value and link with histological lesions. 62
36160755 2022
34
In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed. 62
35704148 2022
35
Defibrotide Shows Efficacy in the Prevention of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study. 62
35953029 2022
36
Hematopoietic stem cell transplantation in serine/threonine kinase 4 (STK4) deficiency: Report of two cases and literature review. 62
36394186 2022
37
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma. 62
36343892 2022
38
Higher Cryopreserved CD34+ Cell Dose Is Associated with Decreased Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Single-Unit Cord Blood Transplantation in Adults Given Prophylactic Ursodeoxycholic Acid and Intravenous Heparin. 62
35995391 2022
39
A stitch in time saves nine: timely use of N-acetyl cysteine (NAC) for chemotherapy-induced veno-occlusive disease (VOD)-is it a cost-effective alternative? 62
35963952 2022
40
Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report. 62
35905554 2022
41
Patient-specific and gene-corrected induced pluripotent stem cell-derived endothelial cells elucidate single-cell phenotype of pulmonary veno-occlusive disease. 62
36400028 2022
42
Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developing during treatment of juvenile dermatomyositis and macrophage activation syndrome: A case report. 62
36416547 2022
43
A rare compound heterozygous EIF2AK4 mutation in pulmonary veno-occlusive disease. 62
36451176 2022
44
A case of glucocorticoid-resistant adult Still's disease complicated by pulmonary hypertension and interstitial lung disease. 62
36250713 2022
45
A case of percutaneous transhepatic stomal varices embolization and partial splenic artery embolization for rectal cancer after CAPOX/BEV chemotherapy: the summary of the stomal varices related to oxaliplatin administration. 62
36266604 2022
46
Plugged percutaneous liver biopsy using Tru-cut needle and coils: A retrospective study. 62
36422847 2022
47
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore). 62
35968907 2022
48
Hematopoietic Stem Cell Transplantation in ARPC1B Deficiency. 62
35767111 2022
49
A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). 62
35635686 2022
50
[Risk factors for acute kidney injury after hematopoietic stem cell transplantation in children: a retrospective study]. 62
36305115 2022

Variations for Hepatic Veno-Occlusive Disease

Expression for Hepatic Veno-Occlusive Disease

Search GEO for disease gene expression data for Hepatic Veno-Occlusive Disease.

Pathways for Hepatic Veno-Occlusive Disease

Pathways related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 VEGFA THPO THBD SERPINE1 SERPINC1 PLG
2 12.57 VEGFA PLG PLAT FGF2 F3
3 11.76 VEGFA SERPINE1 CXCL8
4 11.73 VEGFA FGF2 CXCL8
5 11.71 SERPINE1 PLAT CXCL8
6 11.65 VEGFA FGF2 CXCL8
7
Show member pathways
11.63 THBD SERPINE1 SERPINC1 PLG PLAT F8
8 11.62 VEGFA CXCL8 ABCB1
9 11.42 VEGFA SERPINE1 ABCB1
10 11.38 FGF2 CXCL8 CSF3
11 11.34 SERPINE1 PLG PLAT CXCL8
12 11.15 VEGFA PLG PLAT FGF2
13 10.82 FGF2 SERPINC1 VEGFA
14 10.61 SERPINE1 PLG PLAT

GO Terms for Hepatic Veno-Occlusive Disease

Cellular components related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.22 VEGFA THPO SERPINE1 SERPINC1 PLG PLAT
2 extracellular space GO:0005615 9.77 VEGFA THPO THBD SERPINE1 SERPINC1 PLG
3 serine protease inhibitor complex GO:0097180 9.56 SERPINE1 PLAT
4 platelet alpha granule lumen GO:0031093 9.56 F8 PLG SERPINE1 VEGFA

Biological processes related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.26 VEGFA HFE FGF2 F3 CXCL8 AZU1
2 positive regulation of angiogenesis GO:0045766 10.07 VEGFA SERPINE1 FGF2 F3 CXCL8
3 positive regulation of protein kinase B signaling GO:0051897 9.91 VEGFA THPO FGF2 F3 CSF3
4 fibrinolysis GO:0042730 9.88 SERPINE1 PLG PLAT
5 negative regulation of plasminogen activation GO:0010757 9.8 SERPINE1 PLAT
6 induction of positive chemotaxis GO:0050930 9.8 AZU1 CXCL8 VEGFA
7 negative regulation of fibrinolysis GO:0051918 9.76 THBD SERPINE1 PLG PLAT
8 trans-synaptic signaling by BDNF, modulating synaptic transmission GO:0099183 9.73 PLAT PLG
9 blood coagulation GO:0007596 9.73 THBD SERPINC1 PLG PLAT F8 F3
10 positive regulation of epithelial tube formation GO:1905278 9.63 VEGFA FGF2
11 hemostasis GO:0007599 9.02 THBD SERPINC1 PLG F8 F3

Molecular functions related to Hepatic Veno-Occlusive Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.9 THPO SERPINE1 PLG PLAT HFE CSF3
2 cytokine activity GO:0005125 9.61 VEGFA THPO FGF2 CXCL8 CSF3
3 heparin binding GO:0008201 9.32 VEGFA SERPINC1 FGF2 CXCL8 AZU1

Sources for Hepatic Veno-Occlusive Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....